{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056519","form_type":"8-K","ticker":"DRIO","cik":"0001533998","company_name":"DarioHealth Corp.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.296534+00:00","generated_at":"2026-06-15T16:39:43.967950+00:00","sec_items":["1.01","1.02","2.03","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DarioHealth completes $15.4M preferred stock placement and $30M credit facility refinancing","bullets":["Raised ~$15.4M via convertible preferred stock (Series B, B-1, B-2, B-3) at $1,000/share; conversion prices $3.334-$3.392.","New $30M secured credit facility from Avenue Venture Funds; $30M initial tranche closed; up to $10M additional available after July 2023.","Proforma cash $60M after transactions; expects cash runway through late 2025; saves ~$6M annually in amortization payments.","Approximately half of preferred shares bought by insiders, including management and board; Avenue receives warrant for 584,882 shares at $3.334."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056519","json":"https://secwatch.observer/filing/0001104659-23-056519.json","markdown":"https://secwatch.observer/filing/0001104659-23-056519.md","text":"https://secwatch.observer/filing/0001104659-23-056519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/tm2314673d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:39:43.967950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd46b23f87d6e7cdaeba33de228a7b829d52388f","claim":"DarioHealth Corp.: Filed certificates of designation for Series B, B-1, B-2, and B-3 Preferred Stock, specifying rights and preferences (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering. On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"governance_change"},{"claim_id":"5391e7d3ff4669369d4cafa2fdd0fe42a4a2f8cd","claim":"DarioHealth Corp. entered into Series B Purchase Agreement with accredited investors (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023, DarioHealth Corp. (the \"Company\") entered into securities purchase agreements (each, a \"Series B Purchase Agreement\") with accredited investors relating to an offering (the \"Offering\") and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the \"Series B Preferred Stock\"), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the \"Series B-1 Preferred Stock\"), and an aggregate of 150 shares of Series B-2 Preferred Stock (the \"Series B-2 Preferred Stock\") at a purchase price of $1,000 for each share of Preferred Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"},{"claim_id":"c50762b3733cac391bc8e96f56ae0692448464bb","claim":"DarioHealth Corp. entered into Series B-3 Purchase Agreement with accredited investors (effective 2023-05-05).","evidence_excerpt":"On May 5, 2023, the Company entered into purchase agreements (the \"Series B-3 Purchase Agreement\" and together with the Series B Purchase Agreement, the \"Purchase Agreement\") with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the \"Series B-3 Preferred Stock\" and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the \"Preferred Stock\"), at a purchase price of $1,000 for each share of Preferred Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923056519/0001104659-23-056519-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors"},{"label":"Effective","value":"2023-05-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}